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INTRODUCTION
Erectile dysfunction (ED), the inability to maintain
sufficient penile erection for satisfactory sexual perfor-
mance, is highly prevalent in the general population,
affecting almost 50% of men in the 40-70 years age range,
which corresponds to approximately 150 million men
worldwide (1,2). More recently, ED has been considered a
manifestation of a functional and/or structural abnormality
affecting penile circulation as part of a more generalized
vascular disorder (2).
Erectile dysfunction, therefore, has been associated with
signs of generalized arterial disease, as it frequently coexists
with diseases with a high component of endothelial
dysfunction, such as coronary artery disease, idiopathic
systemic arterial hypertension, atherosclerosis, and end-
stage chronic kidney disease (ESCKD). ED is also associated
with cardiovascular disease risk factors, such as diabetes
mellitus, dyslipidemia, and smoking (1-3).
Erectile dysfunction prevalence rates in men with chronic
kidney disease (CKD) may reach 70-80%, with similar rates
having been reported for those with ESCKD. A number of
factors have been implicated in the development of ED in
these patients, including the actual presence of a chronic
disease, drugs, increased parathyroid hormone (PTH)
serum levels, zinc deficiency, decreased testosterone serum
levels, increased serum prolactin levels, and psychological
factors (3,4).
MATERIALS AND METHODS
This study assessed the prevalence rate of ED in stage 3, 4,
and 5 CKD outpatients and sought to identify the associa-
tions among ED, CKD stage, and comorbidities. ED was
graded according to the International Index of Erectile
Function (IIEF), which was validated for use in Portuguese
(5).
We assessed 81 patients with a mean age of 61.7¡11.6
years (range: 21-84). The results included an estimated ED
rate of 70%, significance level of 0.05, presumed error
margin of 5%, and a population of 163 elements. The study
databank was statistically analyzed with SPSS 13.0 software.
For descriptive and bivariate analyses, only the valid cases
were used. Logistic regression was used to characterize the
relative weight of several variables studied on outcomes
among the group of interviewed subjects. This study was
approved by the ethics committee of the University Hospital
of the Federal University of Juiz de Fora. During the history-
taking visit, each subject received an explanation of the
study and the shared patient/researcher responsibility in
the study’s success. Informed consent authorizing data
collection was then obtained.
RESULTS
The prevalence of erectile dysfunction among those
individuals aged 61 years or older was 85.1% compared
with 66.7% of those ranging from 21 to 60 years in age
(p=0.052). The sample size may not have been sufficiently
large to demonstrate a significant difference between the
groups, as indicated in the literature. The prevalence of ED
was 76.5% (62 patients), with 72.3% classified as stage 3
CKD, 81.5% as stage 4 CKD, and 85.7% as stage 5 CKD,
although no statistically significant difference was found.
Nineteen patients (23.5%) had no ED; 24 (29.6%) had mild
ED; 15 (18.5%) had mild/moderate ED; 13 (16%) had
moderate ED; and 10 (12.3%) had severe ED. Our study did
not demonstrate any association between ED and most
comorbidities considered to impart important cardiovascu-
lar risk, except diabetes mellitus, which reached significance
as both a cause (p=0.004) of kidney disease and comorbidity
(p=0.006; Tables 1 and 2).
Of the 81 patients assessed, 59 were aware of their CKD
for 60 months at most. Among these patients, 86.4% had ED,
while 50% of those aware of their CKD for longer than 61
months had ED (p=0.001). Sixty-three patients were
followed-up as outpatients for 60 months at most; 82.5%
had ED compared with 55.6% of those followed up for
longer than 61 months (p=0.017; Table 3).
The logistic regression model revealed that among
subjects with ED, those with diabetes mellitus were 4.05
times more likely to have ED than non-diabetic subjects
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181(p=0.048). However, subjects aware of their CKD for a
period of less than 60 months were 3.5 times more likely to
have ED than those who were aware of their CKD for longer
periods (p=0.012; Table 4).
DISCUSSION
The high prevalence of ED (76.5%) among CKD patients is
compatible with published reports (4). The prevalence of ED
among those who were aware of their CKD for less than 60
months was higher than that among subjects who were
aware of their CKD for 61 months or more. The former group
was 3.5 times more likely to have ED (p=0.012; CI 1.4–
14.489). These data may indicate greater clinical, metabolic,
and inflammatory imbalances among those who were more
recently aware of their CKD and consequently had shorter
follow-up times, a condition that theoretically favors a higher
prevalenceof ED(4,7-9).Therefore,thistrendmayalsoreflect
a major public health issue, because these patients are likely
to require specialized treatment. This study found a 93.6%
ED prevalence rate among 31 patients with diabetes mellitus
as a cause of their CKD, compared with a 66% ED prevalence
rate among non-diabetic subjects (p=0.004). For those with
diabetes mellitus as a comorbidity, the prevalence of ED was
93,5%, which is in agreement with the literature (3,4).
Diabetic patients were 4.05 times more likely to have ED
compared with non-diabetic subjects.
In conclusion, our study found a high prevalence rate of
ED among CKD patients on conservative treatment. There
was a strong association with diabetes mellitus, either as a
cause of the renal disease or as a comorbidity, and disease
duration. We understand that inflammation, which is
common in these patients (6-8), may account for the high
prevalence rate of ED in this study. The presence of
inflammation may point to the possibility of an early
diagnosis of a generalized endothelial disease that is
amenable to screening at the first nephrological consultation
through a simple but efficient clinical approach.
The utilization of 5-phosphodiesterase inhibitors repre-
sents a novel therapeutic approach used to improve
endothelial function (10). When administered daily to
CKD patients, this treatment can prevent or delay the
development of kidney disease as a consequence of reduced
inflammation in the endothelium.
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Table 1 - Bivariate analysis of the association between
erectile dysfunction and diabetes mellitus.
Variable
With dysfunction
N (%) p-value
Diabetes
mellitus
YES 29 (93.6) 0.004*
NO 33 (66.0)
Table 2 - Bivariate analysis of the association between
erectile dysfunction and other variables.
Variables
% with Erectile
Dysfunction p-value
DM
2 93.5 0.006
*
Caucasian 77.2 0.832
Smoker (current or former) 78.9 0.631
SAH
1 77.6 0.367
Dyslipidemia 71.4 0.619
CAD
3 85.7 0.549
PVD
4 100 0.125
Stroke
5 66.7 0.553
ACEI
5 79.3 0.351
ARB
6 76.3 0.964
CCB
7 69.4 0.177
Diuretics 77.6 0.619
ALPHA-ADREN
8 83.3 0.683
BETA-BLOCK
9 82.8 0.324
Vasodilator 100 0.256
Nitrate 100 0.329
*p-value,0.05.
1-Systemic Arterial Hypertension; 2-Diabetes Mellitus; 3-Coronary Artery
Disease; 4-Peripheral Vascular Disease; 5-Angiotensin-converting Enzyme
Inhibitor; 6-Angiotensin Receptor Blocker; 7-Calcium-Channel Blocker; 8-
Alpha-adrenergics; 9-Beta-blocker.
Table 3 - Bivariate analysis of the association among
erectile dysfunction, the length of disease and the length
of follow-up.
Variable
With
dysfunction p-value
Length of
disease
Less than 60 months 51(86.4) 0.001*
Equal to or more than
61 months
11(50)
Length of
follow-up
Less than 60 months 52(82.5) 0.017*
Equal to or more than
61 months
10(55.6)
*p-value,0.05.
Table 4 - Logistic regression model for the association
between erectile dysfunction, diabetes mellitus and the
duration of chronic kidney disease.
Variable
Odds
ratio p-value CI (95%)
Diabetes
Mellitus
Yes 4.05 0.048* 1.017 – 25.085
No 1
Length of
Disease
Less than 60 months 3.50 0.012* 1.400 – 14.489
Equal to or more
than 61 months
1
Analysis in relation to the ‘‘with erectile dysfunction’’ group of
individuals.
*p-value,0.05.
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